Day One Biopharmaceuticals Statistics
Share Statistics
Day One Biopharmaceuticals has 100.85M shares outstanding. The number of shares has increased by 15.4% in one year.
| Shares Outstanding | 100.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 14.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 72.64M |
| Failed to Deliver (FTD) Shares | 1.66K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 18.10M, so 17.95% of the outstanding shares have been sold short.
| Short Interest | 18.10M |
| Short % of Shares Out | 17.95% |
| Short % of Float | 24.91% |
| Short Ratio (days to cover) | 18.17 |
Valuation Ratios
The PE ratio is -6.17 and the forward PE ratio is -13.96.
| PE Ratio | -6.17 |
| Forward PE | -13.96 |
| PS Ratio | 0 |
| Forward PS | 3.9 |
| PB Ratio | 3.36 |
| P/FCF Ratio | -7.76 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Day One Biopharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.72, with a Debt / Equity ratio of 0.
| Current Ratio | 12.72 |
| Quick Ratio | 12.72 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.55% and return on capital (ROIC) is -59.39%.
| Return on Equity (ROE) | -0.55% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -59.39% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.09M |
| Employee Count | 174 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.89% in the last 52 weeks. The beta is -1.52, so Day One Biopharmaceuticals 's price volatility has been lower than the market average.
| Beta | -1.52 |
| 52-Week Price Change | -19.89% |
| 50-Day Moving Average | 13.45 |
| 200-Day Moving Average | 14.19 |
| Relative Strength Index (RSI) | 24.66 |
| Average Volume (20 Days) | 1.08M |
Income Statement
| Revenue | n/a |
| Gross Profit | -383.00K |
| Operating Income | -206.06M |
| Net Income | -188.92M |
| EBITDA | -206.06M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.37 |
Balance Sheet
The company has 230.78M in cash and 408.00K in debt, giving a net cash position of 230.38M.
| Cash & Cash Equivalents | 230.78M |
| Total Debt | 408.00K |
| Net Cash | 230.38M |
| Retained Earnings | -458.58M |
| Total Assets | 600.81M |
| Working Capital | 541.25M |
Cash Flow
In the last 12 months, operating cash flow was -146.85M and capital expenditures -3.22M, giving a free cash flow of -150.08M.
| Operating Cash Flow | -146.85M |
| Capital Expenditures | -3.22M |
| Free Cash Flow | -150.08M |
| FCF Per Share | -1.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DAWN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -21.24% |
| FCF Yield | -13.33% |
Analyst Forecast
The average price target for DAWN is $38, which is 240.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 240.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 15.59 |
| Piotroski F-Score | 2 |